Tirzepatide emerges a groundbreaking treatment agent for individuals struggling type 2 diabetes. As a dual agonist, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide https://keiranytda041980.dailyhitblog.com/46179993/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist